Which monoclonal antibody targets CD20 on B cells in non-Hodgkin lymphoma?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $24.99Unlock all

Get ready for the Chemotherapy and Radiation Therapy Test with our resources. Study with flashcards and multiple choice questions. Each question includes detailed hints and explanations to help you succeed!

Multiple Choice

Which monoclonal antibody targets CD20 on B cells in non-Hodgkin lymphoma?

Explanation:
Targeting CD20 on B cells is achieved with rituximab. CD20 is a surface antigen present on most mature B cells and many B-cell non-Hodgkin lymphomas, making it an ideal, selective target. Rituximab binds to CD20 and recruits immune effectors like natural killer cells and complement, leading to B-cell depletion through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, with additional potential direct pro-death signaling. This reduces the malignant B-cell population and often improves responses when combined with chemotherapy. The other antibodies act on different targets: cetuximab binds EGFR, used in some solid tumors; trastuzumab targets HER2/neu, used in HER2-positive breast and gastric cancers; bevacizumab targets VEGF, inhibiting angiogenesis. None of these target CD20, so they’re not the choice for B-cell non-Hodgkin lymphoma.

Targeting CD20 on B cells is achieved with rituximab. CD20 is a surface antigen present on most mature B cells and many B-cell non-Hodgkin lymphomas, making it an ideal, selective target. Rituximab binds to CD20 and recruits immune effectors like natural killer cells and complement, leading to B-cell depletion through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, with additional potential direct pro-death signaling. This reduces the malignant B-cell population and often improves responses when combined with chemotherapy.

The other antibodies act on different targets: cetuximab binds EGFR, used in some solid tumors; trastuzumab targets HER2/neu, used in HER2-positive breast and gastric cancers; bevacizumab targets VEGF, inhibiting angiogenesis. None of these target CD20, so they’re not the choice for B-cell non-Hodgkin lymphoma.

More Multiple Choice Questions
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy